Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Merger or Acquisition (April 2025)
31 slides from Genedx's merger presentation, Apr 16, 2025
Slide 1: GeneDx to acquire Fabric Genomics
A new era in genomic medicine: decentralized AI-powered interpretation with centralized intelligence GeneDx to acquire Fabric Genomics April 16, 2025
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws, including statements regarding GeneDx's agreement to acquire Fabric Genomics ("Merger") and the transactions contemplated thereby, including statements regarding the an
Slide 3: We envision a world where any genetic disorder is diagnosed quickly
We envision a world where any genetic disorder is diagnosed quickly to prevent disease progression and ensure long and healthy lives for all. 3
Slide 4: GeneDx is uncovering genetic diagnoses with an industry-leading interpretation engine
GeneDx is uncovering genetic diagnoses with an industry- leading interpretation engine >750K Pay-it-forward data strategy: The snowball exomes & genomes effect of data accumulated with every patient tested drives our underlying interpretation platform to get smarter, faster, and more scalable. Each
Slide 5: Decentralized testing with centralized intelligence, accelerating diagnoses globally
Decentralized testing with centralized intelligence, accelerating diagnoses – globally 5
Slide 6: Two companies, one shared goal: earlier diagnoses for all
Two companies, one shared goal: earlier diagnoses for all Largest rare disease database in the US AI driven interpretation-as-a-service platform Proprietary genotypic and phenotypic Cloud based, turnkey, scalable, dataset informing interpretation sequencer-agnostic platform State of the art, automat
Slide 7: Full spectrum of genomics offerings, from centralized lab to decentralized interpretation
GeneDx + Fabric Genomics will create a full spectrum of genomics offerings, from GeneDx's centralized lab to decentralized interpretation-as-a-service Ultimately, this model will accelerate faster and earlier diagnosis of genetic disease, delivering improved outcomes for pati ents and reducing unnec
Slide 8: The acquisition will expand GeneDx's addressable market with multiple scalable revenue streams
The acquisition will expand GeneDx’s addressable market with multiple scalable revenue streams NICU Genomic Genomic Newborn Decentralization Drives Platform Economics at Testing Screening (gNBS) Global Commercial Scale Expansion With Fabric Genomics' GeneDx’s leadership in early Fabric Genomics’ clo
Slide 9: Combining GeneDx and Fabric Genomics will unlock leverage within both companies
Combining GeneDx and Fabric Genomics will unlock leverage within both companies o Complete suite of solutions for hospital systems including full outsourcing, software-as-a-service Suite of Solutions and interpretation-as-a-service o Merging of data and technology from both companies will enable eac
Slide 10: Terms of the Transaction
Terms of the Transaction Purchase price of $33 million upfront with total consideration to reach up to a potential $51 million in the aggregate, payable as follows: $33 million in cash at closing (subject to customary adjustments for cash, debt, transaction expenses and working capital); Up to a max
Slide 11: Healthcare is at an inflection point
Healthcare is at an inflection point where integrating genomic insights into standard care is becoming essential – both for better clinical outcomes and for saving the healthcare system valuable dollars. Together, GeneDx and Fabric Genomics are positioned to transform access to genomic testing globa
Slide 12: Appendix
Appendix 12
Slide 13: 1 in 10 families face an unnecessary diagnostic journey
1 in 10 families face an unnecessary diagnostic journey On average: 16 tests and 5 years before an accurate diagnosis X X X X X X X X X GeneDx can provide 1 year 3 years 5 years an answer in days 2 years 4 years X X X X X X 13 References: 1. Marwaha S, Knowles JW, and Ashley EA. A gu ide for the dia
Slide 14: The diagnostic odyssey: common, critical, and costly
The journey to an accurate diagnosis can take up to five years.1 3x On their journey to a The diagnostic odyssey: diagnosis, rare disease common, critical, and costly patients will be misdiagnosed an average of three times.2 Millions of Americans with a rare 5 years disease are urgently searching fo
Slide 15: Exome and genome testing offer answers sooner
Exome and genome testing offer answers sooner—leading to more effective treatments and more efficient healthcare spend Recommended by leading medical Superior diagnostic rate for many indications including: societies as a first-line test: Developmental delay Intellectual disability Epilepsy …and mor
Slide 16: Common diseases are in fact a constellation of genetic diagnoses
Common diseases are in fact a constellation of genetic diagnoses One example is epilepsy. At least 768 different genes are related to seizures. Only 43% of epilepsy genes are tested on many commercial epilepsy panels 16 Reference: Butler L. et al. Exome-based testing for patients with seizures: Adva
Slide 17: Common diseases are in fact a constellation of genetic diagnoses
Common diseases are in fact a constellation of genetic diagnoses One example is epilepsy. At least 768 different genes are related to seizures. Only 43% of epilepsy genes are tested on many commercial epilepsy panels Exome and genome sequencing checks all 768 genes 17 Reference: Butler L. et al. Exo
Slide 18: GeneDx has spent over a decade solving for the limitations of the past
GeneDx has spent over a decade solving for the limitations of the past and we're working to change the perception of exome and genome sequencing Then Now Results take months GeneDx delivers results in hours, days or weeks Turnaround time GeneDx’s tests are accessible and widely Tests are prohibitive
Slide 19: Accelerating and deepening our competitive advantage with every patient
Accelerating and deepening our competitive advantage with every patient Pay it forward data strategy: the snowballing effect of data accumulated with ever patient we test drives our underlying interpretation platform to get smarter, faster, and more scalable That’s enable us to identify more than >7
Slide 20: Our data is unmatched in size, breadth, and depth
Our data is unmatched in size, breadth, and depth— making it highly infeasible for competitors to recreate • Enriched for rare disease Diagnosing even the rarest conditions for 25 years • 60% of our exomes/genomes are parent/child trios Enabling de novo findings, sequencing asymptomatic parents • 6
Slide 21: Our market opportunity is massive and poised to expand over time
Our market opportunity is massive and poised to expand over time Taking a disciplined approach entering markets as reimbursement pathways open Rolling expansion of exome/genome use cases fuels a: Historical Near Mid Long base term term term Expert geneticists Pediatric specialties (e.g., autism, e
Slide 22: Payor coverage for exome and genome sequencing is expanding
Payor coverage for exome and genome sequencing is expanding 〉 GeneDx is contracted with 80% of covered lives, including all large national commercial payers 〉 Medicaid and commercial insurance coverage continues to grow for exome and genome o 32 states cover exome or genome sequencing • In Q4, Monta
Slide 23: Medicaid programs across the country are expanding access
Medicaid programs across the country are expanding access Current Medicaid Coverage Landscape Exome or Genome Sequencing Rapid Genome Sequencing Both No Coverage New or Enhanced Coverage 23 Data through February 2025
Slide 24: Outpatient market expansion: Fueling growth with new indications, coverage and guidelines
Outpatient market expansion: Fueling growth with new indications, coverage and guidelines Today, GeneDx primarily targets epilepsy, autism and intellectual disability/developmental delay, congenital anomalies, and rare disease • We have 80% market share among genetics experts, 13% among pediatric ne
Slide 25: Inpatient (NICU) market expansion
Inpatient (NICU) market expansion: A clear unmet need, underscored by decades of earned trust and improved workflows 60% of infants in Level IV NICUs should receive a rapid genome test 1 • Genome testing is severely underutilized, currently ordered for <5% of children who could benefit2 GeneDx has d
Slide 26: Genetic evidence improves the therapeutic development process
Genetic evidence is one of the most powerful tools to improve the therapeutic development process Tomorrow Today Including genetic evidence can The average therapeutic dramatically reduce cost, shorten development cycle: timelines, and improve success rates: Costs $2.6B Genetic evidence can reduce o
Slide 27: Partnerships with biopharma companies help accelerate treatments
Our partnerships with biopharma companies help accelerate treatments— from early discovery through commercialization Our collaborations are impacting the lives of patients today: Akouos (Eli Lilly) Regeneron GeneDx partnered with Akouos to Through a data partnership with GeneDx, match patients with
Slide 28: We believe in a future where every newborn's genome is sequenced at birth
We believe in a future where every newborn’s genome is sequenced at birth Every year, thousands of newborns with actionable conditions are missed by traditional newborn screening (NBS). Federal NBS guidelines recommend testing for 37 conditions with biomarkers—measurable changes in the baby’s blood
Slide 29: GeneDx is the leader set to revolutionize newborn screening
GeneDx is the leader set to revolutionize the standard approach to today's newborn screening, enabling diagnoses before symptoms even start GeneDx has screened more newborns than any other commercial laboratory. This experience gives GeneDx a deep understanding of how to offer this testing at scale
Slide 30: Multiple drivers to profitable, sustainable growth
Expanding serviceable market o New use cases/ indications / call points stemming from emerging guidelines, expanding and, secular tailwinds towards greater acceptance of exome/genome o The American Academy of Pediatrics last issued their genetic testing guidelines in 2014. An update in support of an
Slide 31: A rare opportunity to fuel seismic healthcare shifts
A rare opportunity to fuel seismic healthcare shifts From years of disease progression early interventions From unnecessary and bloated health costs streamlined economic efficiency to From generalized treatments precision medicines From diagnosing symptomatic disease universal genomic newborn screen